1. Generics Bulletin
  2. >>Business

Neuraxpharm Targets Austria With Easypharm Deal

CNS Specialist Underlines OTC Ambitions With Easypharm Acquisition

 
• By Tom Gallen and Dave Wallace

Neuraxpharm has opened a unit in Austria after snapping up local consumer healthcare specialist Easypharm.

Map_Pin_Austria
Neuraxpharm has opened a unit in Austria after acquiring Easypharm • Source: Shutterstock

Neuraxpharm is taking its first steps into Austria and continuing its push into Europe’s branded OTC market by opening a dedicated Austrian subsidiary after acquiring consumer healthcare specialist Easypharm for an undisclosed sum.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Despite Multiple Headwinds, Formycon Remains Positive For Its Biosimilars Growth

 
• By Urtė Fultinavičiūtė

Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.

Celltrion Unveils Strategy Amid Series Of Milestones

 
• By Adam Zamecnik

South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.

Samsung Rolls Out Second US Soliris Biosimilar – At 30% WAC Discount

 
• By Dean Rudge

Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.